Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: Phenotypic-genotypic correlates

British Journal of Clinical Pharmacology

Volumn 56, Issue 1, 2003, Pages 78-83

  Balram, C ^a   Sharma, A ^b   Sivathasan, C ^c   Lee, Edmund J D ^d  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b PFIZER INC   (United States)

^c DEPARTMENT OF CARDIOLOGY   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Asian population; Cyclosporin A; CYP3A4; Ethnicity; Mdr1 gene; P glycoprotein; Pharmacokinetics

Indexed keywords

CYCLOSPORIN A; CYTOSINE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; THYMINE;

AREA UNDER THE CURVE; ARTICLE; ASIAN; CHI SQUARE TEST; CHINESE; DNA SEQUENCE; DRUG BLOOD LEVEL; ETHNIC DIFFERENCE; ETHNIC GROUP; EXON; GENE FREQUENCY; GENOTYPE; HEART TRANSPLANTATION; HUMAN; INDIAN; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ASIA; CYCLOSPORINE; EXONS; GENE FREQUENCY; GENES, MDR; GENETICS, POPULATION; GENOTYPE; HEART TRANSPLANTATION; HOMOZYGOTE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 0038336616     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01820.x     Document Type: Article

References (22)

1. Higgins CF. ABC transporters: from microorganisms to man. Annu Rev Cell Biol 1992; 8: 67-113.
2. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455: 152-162.
3. Patel NH, Rothernberg ML. Multidrug resistance in cancer chemotherapy. Invest New Drugs 1994; 12: 1-13.
4. Silverman JA, Schrenk D. Hepatic canalicular membrane 4: expression of the multidrug resistance genes in the liver. FASEB J 1997; 11: 308-313.
5. Cordon-Cardo C, O'Brien JP, Boccia J, et al. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumour tissues. J Histochem Cytochem 1990; 38: 1277-1287.
6. Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localisation of the multidrug resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735-7738.
7. Schinkel AH, Smitt JJ, van Tellingen O, et al. Disruption of the mouse MDR1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77: 491-502.
8. Fojo AT, Ueda K, Slamon DJ, et al. Expression of a multidrug-resistance gene in human tumours and tissues. Proc Natl Acad Sci USA 1987; 84: 265-269.
9. Lown KS, Mayo RR, Leitchman AB, et al. Role of intestinal P-glycoprotein (MDR 1) in interpatient variation in the oral bioavailability of cyclosporin A. Clin Pharmacol Ther 1997; 62: 248-260.
10. Sparreboom A, van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 1997; 94: 2031-2035.
11. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-427.
12. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-3478.
13. Ameyaw MM, Regateiro F, Li T, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001; 11: 217-221.
14. Schaeffeler E, Eichelbaum M, Brinkmann U, et al. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 2001; 358: 383-384.
15. Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69: 169-174.
16. Johnston A, Sketris I, Marsden JT, et al. A limited sampling strategy for the measurement of cyclosporin AUC. Transplant Proc 1990; 22: 1345-1346.
17. Cooney GF, Jeevanandam V, Choudhury S, Feutren G, Mueller EA, Eisen HJ. Comparative bioavailability of Neoral and Sandimmune in cardiac transplant recipients over one year. Transplant Proc 1998; 30: 1892-1894.
18. Vickers AEM, Alegret M, Meyer E, Smiley S, Guerter J. Hydroxyethyl cyclosporin A induces and decreases P4503A and p-glycoprotein level in rat livers. Xenobiotica 1996; 26: 27-39.
19. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumours by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998; 90: 1225-1229.
20. Sata F, Sapone A, Elizondo G, et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 2000; 67: 48-56.
21. Stein CM, Sadeque AJ, Murray JJ, Wandel C, Kim RB, Wood AJJ. Cyclosporin pharmacokinetics and pharmacodynamics in African American and white subjects. Clin Pharmacol Ther 2001; 69: 317-323.
22. Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nature Med 2001; 7: 584-590.